We investigated the influence of EZH2/1 restriction on cell motility and EMT to determine whether the EZH2/NF‐κB/NKILA signaling axis can be manipulated to enhance therapeutic intervention in breast cancer. This evidence concerns the gene EZH2 and breast carcinoma.